SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced the initiation of its first Phase III trial designed to evaluate the safety and efficacy of pimavanserin as a treatment for Parkinson’s disease psychosis (PDP).
